NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June

NextCure, Inc.

2026-Q1 EPS reported -$1.87

Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.
Net loss $9.8M (vs $11.0M YoY); R&D $6.8M, G&A $3.3M, both down vs prior year.
SIM0505 (CDH6 ADC) granted FDA Fast Track for platinum-resistant ovarian cancer; Phase 1 dose optimization initiated May 2026.
Initial Phase 1 dose escalation data for SIM0505 to be presented at ASCO 2026 on June 1, 2026, including US and China patients.
LNCB74 (B7-H4 ADC) Phase 1 dose escalation enrollment ongoing; trial progress update expected in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.